RG
RGEN.US Repligen Corporation
- Market cap
- USD 10.4B
- P/E
- -
- P/B
- 4.97x
- ROE
- -1.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RGEN.US undervalued?
Graham numberThe Graham number of Repligen Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Repligen Corporation fundamental analysis
No fundamental analysis for Repligen Corporation yet.
Repligen Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a …
Full company profileRepligen Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Repligen Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 105M | 141M | 194M | 270M | 366M | 671M | 802M | 632M | 634M | 738M | 810M |
| Gross Profit | 57.4M | 74.2M | 108M | 138M | 194M | 391M | 456M | 278M | 275M | 348M | 424M |
| Operating Income | 16.0M | 14.0M | 26.0M | 40.1M | 81.3M | 167M | 225M | 47.7M | -35.1M | 59.6M | 493K |
| EBITDA | 24.6M | 24.2M | 41.8M | 56.3M | 98.4M | 203M | 277M | 145M | 80.3M | 183M | 102M |
| Net Income | 11.7M | 28.4M | 16.6M | 21.4M | 59.9M | 128M | 186M | 35.6M | -25.5M | 48.9M | -33.5M |
| EPS | 0.34 | 0.72 | 0.37 | 0.44 | 1.11 | 2.24 | 3.24 | 0.63 | -0.46 | 0.86 | -0.59 |
| Balance Sheet | |||||||||||
| Total Assets | 289M | 120M | 139M | 1.40B | 1.90B | 2.36B | 2.53B | 2.83B | 2.83B | 2.95B | 2.93B |
| Total Liabilities | 120M | 152M | 159M | 340M | 374M | 608M | 621M | 866M | 857M | 844M | 835M |
| Shareholders' Equity | 169M | -31.5M | 616M | 1.06B | 1.53B | 1.75B | 1.91B | 1.96B | 1.97B | 2.11B | 2.09B |
| Cash & Short-term Investments | 142M | 174M | 194M | 528M | 717M | 604M | 624M | 751M | 757M | 768M | 863M |
| Total Debt | 95.3M | 99.3M | 103M | 263M | 275M | 366M | 423M | 712M | 686M | 690M | 692M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.52M | 17.5M | 32.8M | 67.2M | 62.6M | 119M | 172M | 114M | 175M | 117M | 139M |
| Capital Expenditure | 4.33M | 5.45M | 14.0M | 23.2M | 26.3M | 67.1M | 133M | 39.0M | 32.9M | 23.5M | 20.0M |
| Free Cash Flow | 3.20M | 12.0M | 18.7M | 44.1M | 36.3M | 51.9M | 38.7M | 74.9M | 142M | 93.9M | 119M |
| Ratios | |||||||||||
| ROE | 6.9% | - | 2.7% | 2.0% | 3.9% | 7.3% | 9.7% | 1.8% | -1.3% | 2.3% | -1.6% |
| ROA | 4.0% | 23.5% | 11.9% | 1.5% | 3.1% | 5.4% | 7.3% | 1.3% | -0.9% | 1.7% | -1.1% |
| Net Profit Margin | 11.2% | 20.1% | 8.6% | 7.9% | 16.4% | 19.1% | 23.2% | 5.6% | -4.0% | 6.6% | -4.1% |
| Debt to Equity | 0.56x | - | 0.17x | 0.25x | 0.18x | 0.21x | 0.22x | 0.36x | 0.35x | 0.33x | 0.33x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Repligen Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 566M | 10 | 1,589.2% |
| 2022 | USD 17.0M | 0.30 | 9.2% |
| 2021 | USD 2.90M | 0.05 | 2.3% |
| 2020 | - | - | - |
| 2019 | USD 490K | 0.01 | 2.3% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Repligen Corporation
- Insiders 4.87%
- Institutions 95.13%
- Public & others 0.00%
- Shares outstanding 63.9M
- Free float 61.0M
Top funds holding RGEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 2.26M | 3.53% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.71M | 2.67% | +0.28% | Sep 2026 |
| Vanguard Small Cap Index | 1.21M | 1.89% | -2.11% | Sep 2026 |
| MFS Mid Cap Growth A | 1.12M | 1.75% | +7.22% | Sep 2026 |
| T. Rowe Price New Horizons | 950K | 1.49% | -12.00% | Sep 2026 |
| Invesco Discovery A | 900K | 1.41% | +10.04% | Sep 2026 |
| Fidelity Contrafund | 852K | 1.33% | +45.27% | Sep 2026 |
| American Funds SMALLCAP World A | 700K | 1.09% | 0.00% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 671K | 1.05% | -5.21% | Sep 2026 |
| Fidelity Select Health Care | 570K | 0.89% | +3.82% | Aug 2026 |
| First Trust NYSE Arca Biotech ETF | 563K | 0.88% | 0.00% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 523K | 0.82% | +1.53% | Sep 2026 |
| Fidelity Select Medical Tech and Devcs | 505K | 0.79% | +1.00% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 473K | 0.74% | -3.07% | Sep 2026 |
| iShares Biotechnology ETF | 467K | 0.73% | +12.17% | Oct 2026 |
| Vanguard Explorer Inv | 450K | 0.70% | +14.18% | Sep 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 417K | 0.65% | +7.61% | Sep 2026 |
| Congress Small Cap Growth Institutional | 385K | 0.60% | 0.00% | Sep 2026 |
| State Street SPDR Port S&P 400 Md CpETF | 342K | 0.53% | 0.00% | Oct 2026 |
| Columbia Small Cap Growth Inst | 321K | 0.50% | -19.45% | Sep 2026 |
Top institutions holding RGEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 5.38M | 8.42% | -10.15% | Jun 2026 |
| FMR Inc | 3.33M | 5.20% | +15.24% | Jun 2026 |
| United Capital Financial Advisers Inc | 2.79M | 4.37% | +0.60% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.41M | 3.77% | +0.61% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.31M | 3.62% | +0.34% | Jun 2026 |
| Maverick Capital Ltd | 1.98M | 3.10% | +30.67% | Jun 2026 |
| State Street Corp | 1.80M | 2.82% | +1.31% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.75M | 2.74% | -64.08% | Jun 2026 |
| Massachusetts Financial Services Company | 1.62M | 2.53% | +15.71% | Jun 2026 |
| Wasatch Advisors LP | 1.59M | 2.49% | +27.88% | Jun 2026 |
| Ameriprise Financial Inc | 1.58M | 2.47% | +70.35% | Jun 2026 |
| Bank of New York Mellon Corp | 1.52M | 2.38% | -0.56% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 1.41M | 2.21% | +3.29% | Jun 2026 |
| Amvescap Plc. | 1.39M | 2.17% | +8.53% | Jun 2026 |
| Holocene Advisors, LP | 1.29M | 2.02% | +82.28% | Jun 2026 |
| RTW INVESTMENTS, LLC | 1.24M | 1.94% | +2.87% | Jun 2026 |
| Geode Capital Management, LLC | 1.06M | 1.66% | -0.19% | Jun 2026 |
| Congress Asset Management Company, LLP | 1.01M | 1.58% | +26.87% | Jun 2026 |
| Conestoga Capital Advisors, LLC | 981K | 1.53% | -10.64% | Jun 2026 |
| The Goldman Sachs Group Inc | 965K | 1.51% | +48.22% | Jun 2026 |
Repligen Corporation company profile
- Company name
- Repligen Corporation
- Ticker
- RGEN.US
- Exchange
- USA Stocks
- Listed since
- Mar 26, 1990
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 2,000
- Fiscal year end
- December
- Address
- Building 1, Waltham, MA, United States, 02453
- Phone
- 781 250 0111
- Website
- repligen.com
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Repligen Corporation management
10- Mr. Olivier LoeillotPresident, CEO & Director · born 1970
- Mr. Jason K. GarlandCFO & Chief Compliance Officer · born 1974
- Mr. James R. BylundChief Operating Officer · born 1963
- Mr. Anthony J. HuntAdvisor · born 1964
- Mr. Ralf KuriyelSenior Vice President of Research & Development · born 1958
- Mr. Brian Robb DouglassSenior VP & Chief Product Officer · born 1975
- Dr. Paul R. Schimmel Ph.D.Founder · born 1941
- Ms. Violetta HughesChief Accounting Officer · born 1973
- Ms. Heather EmsChief Information Officer
- Mr. Jacob K. Johnson C.F.A.Vice President of Investor Relations